baber/WOPTO huggingface dataset:
Patent AT-E252269-T1 (AT)
Inventor: GUDESEN HANS GUDE
IPC: G02B5/18
Filed: 1996-06-24
Granted: 2003-11-15
Abstract: PCT No. PCT/NO96/00155 Sec. 371 Date Dec. 23, 1997 Sec. 102(e) Date Dec. 23, 1997 PCT Filed Jun. 24, 1996 PCT Pub. No. WO97/01171 PCT Pub. Date Jan. 9, 1997In an optical data storage medium with a storage area formed from a transparent, homogenous base material and with a number of optically active structures at one side of the storage area, the optically active structures are diffractive optical elements which can focus a beam of light incident on the storage area on to one or more points in the storage area and/or a redirected beam of light or emitted light radiation from this or these points on to a point outside the optical storage medium. During writing/reading of data in the storage medium, the diffractive optical elements are used for focusing the write/read beam in order to generate a data carrying structure or read data stored in such a data carrying structure, respectively. By exploiting the special optical properties of diffractive optical elements, it is possible to achieve parallel writing/reading of data, possibly in several parallel storage layers in the optical storage medium or randomly distributed therein, the optical storage medium thus providing a genuine volumetric storage and a corresponding genuine volumetric accessing of the stored data.
Patent AT-E178620-T1 (AT)
Inventor: DANNER BERNARD
IPC: C08F20/26
Filed: 1996-06-13
Granted: 1999-04-15
Abstract: (Co)poly-alpha-hydroxyacrylic-acid-based polymers (P), optionally in lactonized form or in salt form, optionally as Mg-complexes, and which are characterized by a content in carbohydrate units and 2-hydroxy-2-carboxyethylene-1,2 monomer units, are suitable as biologically degradable, alkali-resistant stabilizers for peroxide bleaching agents.
Patent AT-E400176-T1 (AT)
Inventor: CAMPBELL KEITH
IPC: A01K67/02
Filed: 1996-08-30
Granted: 2008-07-15
Abstract: A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the GO or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.
Patent AT-E221570-T1 (AT)
Inventor: FENNEY MICHAEL KEITH
IPC: C11D7/20
Filed: 1996-09-03
Granted: 2002-08-15
Abstract: The invention relates to a granular detergent composition comprising (i) a softening clay and (ii) a clay flocculating polymer, and to a process for making the composition. The composition is particularly useful in "softening-through-the-wash" products. The clay flocculating polymer is sieved or ground such that at least 95 % by weight of the clay flocculating polymer has a particle size of less than 250 micrometers, and preferably less than 150 micrometers, before adding it to the granular detergent composition.
Patent AT-E216256-T1 (AT)
Inventor: LEHMANN PAUL
IPC: G01N33/84
Filed: 1996-09-12
Granted: 2002-05-15
Abstract: The present invention is directed to a pharmaceutical combination preparation comprising 2,000-7,000 U of recombinant human erythropoietin (EPO) and 5-20 mg of an Fe(III) complex, wherein the rhEPO and the Fe(III) complex may be present in separate administration forms or in an integrated administration form.The pharmaceutical preparation is used in the treatment of anemias or hemodialysis patients.
Patent AT-E283346-T1 (AT)
Inventor: KIDD GEOFFREY L
IPC: B01L3/14
Filed: 1996-09-20
Granted: 2004-12-15
Abstract: A container suitable for high speed centrifugation is provided with a cap carrying a microbe-impermeable filter means. The filter means permits gas flow into and out of the container but prevents microbes from entering the container. A method of making such a container is also described. A preferred embodiment is for a container that can be used as a microcentrifuge tube. A method of drying, e.g., lyophilizing, a biological sample using the container is also provided.
Patent AT-E188438-T1 (AT)
Inventor: FLUECKIGER RUDOLF
IPC: B65D75/52
Filed: 1996-12-12
Granted: 2000-01-15
Abstract: PCT No. PCT/CH96/00435 Sec. 371 Date May 18, 1998 Sec. 102(e) Date May 18, 1998 PCT Filed Dec. 12, 1996 PCT Pub. No. WO97/22537 PCT Pub. Date Jun. 26, 1997To find the core temperature of the foodstuff, the package can be fitted with an aperture (3) through which a temperature sensor (11) is inserted into the foodstuff. The temperature sensor is connected to a temperature detection instrument at an end projecting from the aperture (3) and the foodstuff heated to the predetermined temperature, the temperature curve being stored in the temperature detection instrument so as to be fetched. For cooling, the foodstuff with the sensor is, for example, taken out of the oven and reconnected to the temperature detector, in which the temperature curve during cooling is stored so as to be fetched.
Patent AT-E364076-T1 (AT)
Inventor: KRIEGER MONTY
IPC: C12N15/09
Filed: 1996-11-15
Granted: 2007-06-15
Abstract: Methods for regulation of lipid and cholesterol uptake are described which are based on regulation of the expression or function of the SR-BI HDL receptor. The examples demonstrate that estrogen dramatically downregulates SR-BI under conditions of tremendous upregulation of the LDL-receptor. The examples also demonstrate the upregulation of SR-BI in rat adrenal membranes and other non-placental steroidogenic tissues from animals treated with estrogen, but not in other non-placental non-steroidogenic tissues, including lung, liver, and skin. Examples further demonstrate the uptake of fluorescently labeled HDL into the liver cells of animal, which does not occur when the animals are treated with estrogen.
Patent AT-E365171-T1 (AT)
Inventor: NG JOHN
IPC: C07J19/00
Filed: 1996-12-11
Granted: 2007-07-15
Abstract: Multiple novel reaction schemes, novel process steps and novel intermediates are provided for the synthesis of epoxymexrenone and other compounds of Formula I wherein: -A-A- represents the group -CHR<SUP>4</SUP>-CHR<SUP>5</SUP>- or CR<SUP>4</SUP>-CR<SUP>5</SUP>- R<SUP>3</SUP>, R<SUP>4 </SUP>and R<SUP>5 </SUP>are independently selected from the group consisting of hydrogen, halo, hydroxy, lower alkyl, lower alkoxy, hydroxyalkyl, alkoxyalkyl, hydroxycarbonyl, cyano, aryloxy, R<SUP>1 </SUP>represents an alpha-oriented lower alkoxycarbonyl or hydroxyalkyl radical, -B-B- represents the group -CHR<SUP>6</SUP>-CHR<SUP>7</SUP>- or an alpha- or beta-oriented group: where R<SUP>6 </SUP>and R<SUP>7 </SUP>are independently selected from the group consisting of hydrogen, halo, lower alkoxy, acyl, hydroxyalkyl, alkoxyalkyl, hydroxycarbonyl, alkyl, alkoxycarbonyl, acyloxyalkyl, cyano, aryloxy, and R<SUP>8 </SUP>and R<SUP>9 </SUP>are independently selected from the group consisting of hydrogen, halo, lower alkoxy, acyl, hydroxyalkyl, alkoxyalkyl, hydroxycarbonyl, alkyl, alkoxycarbonyl, acyloxyalkyl, cyano, aryloxy, or R<SUP>8 </SUP>and R<SUP>9 </SUP>together comprise a carbocyclic or heterocyclic ring structure, or R<SUP>8 </SUP>or R<SUP>9 </SUP>together with R<SUP>6 </SUP>or R<SUP>7 </SUP>comprise a carbocyclic or heterocyclic ring structure fused to the pentacyclic D ring.
Patent AT-E250782-T1 (AT)
Inventor: ZOCCA RINALDO
IPC: G06K7/015
Filed: 1997-01-17
Granted: 2003-10-15
Abstract: A scanner for the acquisition of optical information, in particular bar codes, is proposed, which has a laser device (3), a receiving device (23), which detects laser light (25) reflected from the surface, carrying the optical information, of the object (13), and a measuring device (27), which emits a control signal corresponding to the distance from the object (13). The scanner (1) is distinguished by the fact that the laser device (3) has a single laser light source (37), and that a focusing device (31) is provided which can receive the control signal of the measuring device (27) and enables the scanner (1) to be adapted to the distance from the object (13), on the surface of which the optical information or the bar code (15) is present. <IMAGE>
Patent AT-E198609-T1 (AT)
Inventor: KLATT MARTIN
IPC: C08J5/00
Filed: 1997-10-10
Granted: 2001-01-15
Abstract: PCT No. PCT/EP97/05605 Sec. 371 Date Apr. 14, 1999 Sec. 102(e) Date Apr. 14, 1999 PCT Filed Oct. 10, 1997 PCT Pub. No. WO98/17719 PCT Pub. Date Apr. 30, 1998Thermoplastic molding compositions comprise A) from 30 to 97% by weight of a polyester, B) from 1 to 30% by weight of melamine cyanurate, C) from 1 to 30% by weight of at least one phosphorus-containing flame retardant which contains phosphorus in the valence state -1, -2 or -3, D) from 0 to 60% by weight of other additives and processing aids, where the total of the percentages by weight of components A) to D) is 100%.
Patent AT-E203315-T1 (AT)
Inventor: ROBINSON EDGAR C
IPC: F23D11/00
Filed: 1997-05-23
Granted: 2001-08-15
Abstract: A powered multi-fuel burner has a burner assembly which utilizes an air aspirated nozzle and an infra-red type configuration. An air compressor provides air to the air aspirated nozzle and a fuel tank holds fuel supplied to the air aspirated nozzle by operation of the suction created at the nozzle. A metering valve is interposed between the fuel tank and the air aspirated nozzle. The metering valve is manually adjustable to increase or decrease the fuel supplied to the nozzle thereby to increase or decrease the heat output of the burner.
Patent AT-E343630-T1 (AT)
Inventor: BOUQUET JEAN-FRANCOIS
IPC: C12N15/09
Filed: 1997-05-22
Granted: 2006-11-15
Abstract: The invention features apoptosis-resistant, non-transformant immortalised avian cells, in particular, avian tissues, i.e., other than blood or haematopoietic cells, particularly fibroblasts and epithelial cells, for instance embryos.
Patent AT-E260614-T1 (AT)
Inventor: RIES MICHAEL D
IPC: A61F2/32
Filed: 1997-05-23
Granted: 2004-03-15
Abstract: The acetabular cup prosthesis comprises a surgically implantable acetabular cup body having an inner surface and an outer convex surface adapted to interface with a patient's pelvic bone tissue. The cup body has an apex, and a base in the form of an annular rim that has a radius. It also has a base centre as origin for the radius, a cup axis which intersects the apex and base centre, and an annular rim periphery. The cup body outer convex surface has first and second curved surface areas. The first curved surface area is nearest the apex and is generated by rotating an arc 360 degrees around the cup axis which intersects the base centre and apex. The arc has a first radius of curvature with a first origin positioned at or near the base centre and its terminal end at the apex. The second curved surface area is positioned next to the base and is generated by rotating an arc 360 degrees around the cup axis. The arc has a second radius of curvature that is larger than the first radius of curvature and with a second origin that is spaced away from the first origin. A smooth transition is provided between the first and second curved surface areas.
Patent AT-E296797-T1 (AT)
Inventor: WU JING
IPC: A61K31/4035
Filed: 1997-11-21
Granted: 2005-06-15
Abstract: Disclosed are compounds which inhibit  beta -amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits  beta -amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions. Said compounds are represented by formula (I), wherein R<1> is selected from the group consisting of: a) alkyl, alkenyl, alkaryl, alkcycloalkyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocyclic; b) a substituted phenyl group of formula (II), wherein R is alkylene of from 1 to 8 carbon atoms, m is an integer equal to 0 or 1, and c) 1- or 2-naphthyl substituted at the 5, 6, 7 and/or 8 positions, R<2> is selected from the group consisting of hydrogen, alkyl of from 1 to 4 carbon atoms, alkylalkoxy of from 1 to 4 carbon atoms, alkylthioalkoxy of from 1 to 4 carbon atoms; and R<3> and R<3'> are independently selected from the group consisting of: (a) hydrogen, (b) alkyl, (c) -(R<7>)n(W)p, wherein R<7> is an alkylene group, W is selected from the group consisting of (i) formula (A); (ii) heteroaryl; and (iii) N-heterocyclic, and n is an integer equal to 0 or 1, and p is an integer equal to 1 to 3; (d) -CH( phi )CH2C(O)O-Q where Q is selected from the group consisting of alkyl, aryl, heteroaryl and heterocyclic; X' is hydrogen, hydroxy or fluoro; X'' is hydrogen, hydroxy or fluoro, or X' and X'' together form an oxo group, Z is selected from the group consisting of a bond covalently linking R<1> to -CX'X''-, oxygen and sulfur.
Patent AT-E290855-T1 (AT)
Inventor: LEHMANN KLAUS DR
IPC: A61K9/00
Filed: 1998-04-07
Granted: 2005-04-15
Abstract: A laminar dosage form (I) for controlled drug release comprising rolled or folded layers of polymer film containing a drug has the following characteristics: (i) the outer surface area (exposed to digestive juices) of the film in its rolled or folded state is at most 25 % of its total surface area; and (ii) the layers are adhered together such that (I), in the release test of USP 23, Method A, Apparatus 2 at 37 degrees C and 50 rpm in simulated gastric juice, remains in its rolled or folded state for at least 1 hour and releases at least 30 % of the contained drug while in the rolled or folded state.
Patent AT-E318358-T1 (AT)
Inventor: GOGGIN CHRISTOPHER M
IPC: E05D15/526
Filed: 1998-10-26
Granted: 2006-03-15
Abstract: In a multi-position window that has a window sash (20) that is rotatable out of the window frame (54) on at least two different axes (70, 72) on pivots which are changed by a drive train (30) on the sash (20) moving to different positions, the device includes one of a spring (48) driven bolt (40) and a strike (22) on the window sash (20) being moved by the drive train (30) into alignment and engagement with the other on the window frame (54) and with a hole (66) for a tool (84) to retract the bolt (40) from the strike (22). <IMAGE>
Patent AT-E306934-T1 (AT)
Inventor: BARINGTON KARINA ALSOE
IPC: A61K38/00
Filed: 1998-12-14
Granted: 2005-11-15
Abstract: The present invention relates to a high-purity von Willebrand factor (vWF) preparation as well as to a process for preparing such preparation. The invention further relates to the use of such preparation for preparing a medicament for the treatment of bleeding disorders and a pharmaceutical composition comprising such preparation suitable for treating these disorders. In a further aspect, the present invention relates to a method for treating bleeding disorders. The bleeding disorder may suitably be von Willebrand's Disease (vWD), haemophilia A induced by vWF-dependent FVIII deficiency or haemophilia A.
Patent AT-E338374-T1 (AT)
Inventor: NICKOLADZE LEO G
IPC: H02P9/00
Filed: 1998-02-06
Granted: 2006-09-15
Abstract: A line synchronous generator with an exciter and generator stage. The exciter stage includes an exciter stator and an exciter rotor, and the generator stage includes a generator stator and generator rotor. In one embodiment, the stators are wound with primary windings for connection to an AC power source and the rotors are wound with secondary windings. In an alternative embodiment, the rotors are wound with primary windings for connection to the AC power source and the stators are wound with secondary windings. The proper phase angle alignment of the secondary windings are determined by connecting the primary windings of the exciter and generator stages to the AC power source, and connecting the a secondary winding of the exciter stage to a secondary winding of the generator stage. The remaining open secondary leads are then tested for two pairs having a voltage equal to two times the line voltage, and two pairs having a voltage equal to  2ROOT 3 times the line voltage. The two pairs of open secondary leads having a voltage equal to two times the line voltage are connected together.
Patent AT-E274716-T1 (AT)
Inventor: FORGETTE JEFFREY A
IPC: G02F1/153
Filed: 1998-03-26
Granted: 2004-09-15
Abstract: An EC variable reflectance mirror (110) for a vehicle includes a reflector/electrode (120) on the third surface (114a) of the mirror. This reflector/electrode forms an integral electrode media, and may be a single layer of a highly reflective material or may comprise a series of coatings. <IMAGE>
Patent AT-E214987-T1 (AT)
Inventor: PUETZ KARL HEINZ
IPC: B21J5/12
Filed: 1998-05-14
Granted: 2002-04-15
Abstract: The invention relates to a flowturning device (1; 101) for producing an internal geared wheel (17) with inner toothing, one set of which is slanted. The workpiece (9) is held by a retaining member (16; 116) during shaping of the first inner toothing. The workpiece (9) is held by the first toothing on the first shaping toot (2; 102) during shaping of the second inner toothing. Once the internal geared wheel (17) has been finished, the rotational coupling between both shaping tools (2, 4; 102, 104) is detached. The internal geared wheel (17) is detached from the slanted toothing(s) by means of a stripping member (18).
Patent AT-E210741-T1 (AT)
Inventor: COLEMAN MICHAEL JOHN
IPC: C22C38/58
Filed: 1998-10-08
Granted: 2001-12-15
Abstract: A first steel comprises 0-0.05 weight % carbon, 0-1.0 weight % silicon, 10.0-20.0 weight % manganese, 13.5-18.0 weight % chromium, 1.0-4.0 weight % nickel, 1.5-3.5 weight % molybdenum and 0.2-0.4 weight % nitrogen. A second steel comprises 0-0.2 weight % carbon, 0-1.0 weight % silicon, 10.0-20.0 weight % manganese, 13.5-18.0 weight % chromium, 1.0-7.0 weight % nickel, 1.5-4.0 weight % molybdenum and 0.2-0.4 weight % nitrogen where nickel equivalence/(chromium equivalence - 1À4) > 1.51 and nickel equivalence + chromium equivalence > 35. Such steels may be used as drill collars in oil and gas drills.
Patent AT-E317671-T1 (AT)
Inventor: HEIM WARREN PAUL
IPC: A61B18/00
Filed: 1998-10-05
Granted: 2006-03-15
Abstract: An electrosurgical system is disclosed that applies electrical energy to obtain a predetermined surgical effect, while also reducing eschar deposits on a working surface of an electrosurgical instrument, producing an eschar deposit which is easily removed from the working surface and/or facilitating removal of eschar deposits during a cleaning procedure. Such benefits may be realized by providing a negative bias on the working surface relative to a return path to source during electrosurgical procedures and/or during a cleaning procedure which may include contacting the working surface with an electrically conductive liquid.
Patent AT-E325198-T1 (AT)
Inventor: DEROSE RICHARD
IPC: A01H5/00
Filed: 1998-12-22
Granted: 2006-06-15
Abstract: The present invention relates to a DNA sequence, a 5' regulatory element allowing the expression of a heterologous gene in a plant cell from a monocotyledonous plant, characterized in that it comprises, in the direction of transcription, a first DNA sequence, which is a functional fragment of the sequence of the maize H3C4 promoter, and a second DNA sequence, which is a functional fragment of the sequence of the first intron of rice actin. The invention also relates to a chimeric gene comprising the said DNA sequence and the plants transformed with the said gene.
Patent AT-E225928-T1 (AT)
Inventor: VORNFETT KARL ULRICH
IPC: F41A19/69
Filed: 1999-04-20
Granted: 2002-10-15
Abstract: The weapon system has an electronic evaluation device (14) for controlling the weapon, whereby the electronic unit (8) in the cartridge (6) is connected to the evaluation device via electrical leads (9,10) and a contact system with a fixed (18) and a movable (21) contact. The fixed contact is a spiral spring attached to the cartridge in a groove in the cartridge base externally covered by an electrically insulating coating. The movable contact is attached to a device mounted on the weapon and has a point that penetrates the insulating coating to contact the first contact and is pressed between adjacent windings of the fixed contact.
Patent AT-E452351-T1 (AT)
Inventor: WEINLAND MICHAEL
IPC: G09F9/33
Filed: 1999-06-19
Granted: 2010-01-15
Abstract: The arrangement has an LED field, the mechanical coupling dimensions and the electrical connection parameters of the existing lighting arrangement is coupled to an electronic adapter circuit (3) and used in place of the existing lighting arrangement. The arrangement can have the mechanical an electrical connections of a conventional fluorescent lamp and carries the adapter circuit on its rear for connection via electrical contact pins (4) to a conventional fluorescent lamp holder.
Patent AT-E299636-T1 (AT)
Inventor: DEAC CORNELIUS
IPC: H04L29/12
Filed: 1999-07-27
Granted: 2005-07-15
Abstract: The procedure comprises the transfer of unitary address information (1,5) within an industrial system utilizing the existing local communication architecture (8,9) and exploiting the data transfer protocols IP, TCP, and UDP.
Patent AT-E259092-T1 (AT)
Inventor: STARCK THIERRY
IPC: H01B17/26
Filed: 1999-12-13
Granted: 2004-02-15
Abstract: The connection comprises a moulded body structure (23) that has limited gas permeability. A number of fins (23C) are formed on the external body section with an electrical conductor (18). mounted within the body section. The connector is mounted to an external metallic wall (17) of a structure.
Patent AT-E402170-T1 (AT)
Inventor: KASSIR JAMAL
IPC: C07D317/44
Filed: 1999-04-15
Granted: 2008-08-15
Abstract: A method for the inhibition of the binding of  alpha 4 beta 1 integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit this binding; pharmaceutically active compositions comprising such compounds; and the use of such compounds either as above, or in formulations for the control or prevention of diseases states in which  alpha 4 beta 1 is involved.
Patent AT-E290216-T1 (AT)
Inventor: HAWKINS PAMELA L
IPC: G01N33/86
Filed: 1999-06-21
Granted: 2005-03-15
Abstract: Coagulation control compositions suitable for use in connection with PT and/or APTT assays are disclosed along with their methods of preparation and methods of use. Preferred coagulation controls comprise plasma and an anticoagulant having activity for enhancing the activity of antithrombin III (ATIII) or of heparin co-factor II (HCII) against thrombin or against a clotting factor selected from the group consisting of factors IXa, Xa and XIa. The anticoagulant is preferably a glycosaminoglycan such as heparin, a heparin derivative or a heparin analog. The anticoagulant is preferably combined with (1) an abnormal plasma (e.g. activated plasma or factor-deficient plasma) and/or (2) a primate plasma (e.g. human plasma), and a non-primate mammalian plasma (e.g. bovine plasma). In the latter case, the non-primate mammalian plasma is preferably present in the coagulation control composition in an amount of not more than about 12% by volume, relative to total volume.